Advertisement
Advertisement
U.S. Markets close in 3 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Hemostemix Inc. (HEM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1600-0.0100 (-5.88%)
As of 12:46PM EDT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1700
Open0.1700
Bid0.1500 x 0
Ask0.1600 x 0
Day's Range0.1500 - 0.1700
52 Week Range0.1300 - 0.4200
Volume119,118
Avg. Volume102,757
Market Cap9.464M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-0.2410
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Hemostemix Announces Exploring Clinical Trial Financing Alternatives

    Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the "Clinical Trial Financing Alternatives"), after retaining experts in the field of biotech business development who have significant experience completing deals on behalf

  • Newsfile

    Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board

    Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board.Dr. von Schwarz is a US based world renowned, triple board certified clinical and academic cardiologist and clinical professor of medicine at UCLA and UC Riverside. He joined Cedars Sinai Medical Center and UCLA ...

  • Newsfile

    Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board

    Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board.Dr. Hébert is the Assistant Dean for Biomedical Science Education in the Faculty of Medicine and Health Sciences at McGill University, the Director of the McGill Regenerative Medicine Network, and a Professor in the Department of Pharmacology and Therapeuti

Advertisement
Advertisement